The invention refers to pharmaceutical industry, specifically to the development of interferon-containing compounds capable to increase their antiviral potency and applicable in ophthalmology for the treatment of viral diseases of the eye. Essence of the invention: eye drops containing recombinant interferon stabilizer of biological and physicochemical properties stabilizer of resistance to microbial contamination, anti-oxidizing agent and buffer solution under the invention, the eye drops contain antihistamine agents selected from the following group: anthazoline, azelastin, tetryzoline, diphenhydramine hydrochloride as stabilizers of biological and physicochemical properties, the product contains agents selected from the following group: low-molecular polyvinyl pyrrolidone, Macrogol 400-12000, propylene glycol as a stabilizer of resistance to microbial contamination the drops contain agents selected from the group: Nipasol, sorbic acid, boric acid. In addition, the eye drops contain sodium chloride and/or sodium acetate with the following component concentrations per ml of the solution: As an anti-oxidizing agent, the eye drops contain Trilon B and/or buthylhydroxytoluene in the amount of 0.0001-0.1 g per ml of the solution. The eye drops contain recombinant interferon selected from the group: alpha-, beta-, gamma-interferon. They also contain acetate borate or phosphate, or borate buffer as a buffer solution.
